This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spaapen, R. Articles by Mutis, T. Search for Related Content PubMed PubMed Citation Articles by Spaapen, R. Articles by Mutis, T.

Rebuilding Human Leukocyte Antigen Class II–Restricted Minor Histocompatibility Antigen Specificity in Recall Antigen-Specific T Cells by Adoptive T Cell Receptor Transfer: Implications for Adoptive Immunotherapy

Authors' Affiliations: Departments of ¹ Clinical Chemistry and Haematology, ² Immunology, and ³ Haematology, University Medical Center Utrecht, the Netherlands

Requests for reprints: Tuna Mutis, University Medical Center Utrecht, Department of Clinical Chemistry and Haematology (G.03.550), Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. Phone: 310-30-2506504; Fax: 310-30-2505418; E-mail: t.mutis{at}umcturecht.nl.

Purpose: Donor T cells directed to hematopoietic minor histocompatibility antigens (mHag) are appealing tools for adoptive immunotherapy of hematological malignancies after allogeneic stem cell transplantation (allo-SCT). Toward the development of a convenient strategy for ex vivo generation of human leukocyte antigen (HLA) class II–restricted mHag-specific T cells, we evaluated the feasibility of rebuilding mHag-specific T cell functions in donor-derived recall antigen-specific T cells via T cell receptor (TCR) transfer.

Experimental Design: TCR - and ß-chains of an HLA-DPB1*0401–restricted T-cell clone recognizing a multiple myeloma-associated mHag were retrovirally transferred into a tetanus toxoid (TT)–specific clone derived from the original stem cell donor. TCR double-transduced cells were compared with the parent mHag- and TT-specific clones for antigen specificity, cytokine secretion, and cytotoxic activity and were analyzed for their in vitro expansion capacity in a TT- or mHag-specific fashion.

Results: mHag-TCR–transduced TT-specific cells displayed both TT and mHag specificity. Similar to the parent cells, they secreted Th-1 cytokines and exerted significant cytotoxic activity against TT-pulsed or mHag⁺ target cells, including multiple myeloma cells. A 4-week expansion of TCR-transduced cells via the TT-specific TCR had no negative influence on the mHag-specific cytotoxic activity and resulted in 10- to 100-fold better cell yields as compared with mHag-specific expansion.

Conclusions: HLA class II–restricted, mHag-specific effector functions can be successfully reconstructed in donor-derived TT-specific T cells via TCR transfer. Effective expansion of these T cells via TT-specific TCRs illustrate the suitability of this strategy for ex vivo expansion and possibly for in vivo TT-specific reboosting of HLA class II–restricted immunotherapeutic T cells.

This article has been cited by other articles:

				R. M. Spaapen, H. M. Lokhorst, K. van den Oudenalder, B. E. Otterud, H. Dolstra, M. F. Leppert, M. C. Minnema, A. C. Bloem, and T. Mutis Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis J. Exp. Med., November 24, 2008; 205(12): 2863 - 2872. [Abstract] [Full Text] [PDF]